158 related articles for article (PubMed ID: 38692813)
1. Molecular Testing in Lung Cancer: Recommendations and Update.
Borczuk AC
Surg Pathol Clin; 2024 Jun; 17(2):307-320. PubMed ID: 38692813
[TBL] [Abstract][Full Text] [Related]
2. Lung Carcinoma Predictive Biomarker Testing by Immunoperoxidase Stains in Cytology and Small Biopsy Specimens: Advantages and Limitations.
Zhou F; Moreira AL
Arch Pathol Lab Med; 2016 Dec; 140(12):1331-1337. PubMed ID: 27588333
[TBL] [Abstract][Full Text] [Related]
3. Non-small cell lung cancer.
Ettinger DS; Akerley W; Borghaei H; Chang AC; Cheney RT; Chirieac LR; D'Amico TA; Demmy TL; Ganti AK; Govindan R; Grannis FW; Horn L; Jahan TM; Jahanzeb M; Kessinger A; Komaki R; Kong FM; Kris MG; Krug LM; Lennes IT; Loo BW; Martins R; O'Malley J; Osarogiagbon RU; Otterson GA; Patel JD; Pinder-Schenck MC; Pisters KM; Reckamp K; Riely GJ; Rohren E; Swanson SJ; Wood DE; Yang SC; Hughes M; Gregory KM;
J Natl Compr Canc Netw; 2012 Oct; 10(10):1236-71. PubMed ID: 23054877
[TBL] [Abstract][Full Text] [Related]
4. Genomic Profiling of Advanced Non-Small Cell Lung Cancer in Community Settings: Gaps and Opportunities.
Gutierrez ME; Choi K; Lanman RB; Licitra EJ; Skrzypczak SM; Pe Benito R; Wu T; Arunajadai S; Kaur S; Harper H; Pecora AL; Schultz EV; Goldberg SL
Clin Lung Cancer; 2017 Nov; 18(6):651-659. PubMed ID: 28479369
[TBL] [Abstract][Full Text] [Related]
5. Molecular testing in lung cancer: fine-needle aspiration specimen adequacy and test prioritization prior to the CAP/IASLC/AMP Molecular Testing Guideline publication.
Rafael OC; Aziz M; Raftopoulos H; Vele OE; Xu W; Sugrue C
Cancer Cytopathol; 2014 Jun; 122(6):454-8. PubMed ID: 24723383
[TBL] [Abstract][Full Text] [Related]
6. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer.
Kerr KM; Bubendorf L; Edelman MJ; Marchetti A; Mok T; Novello S; O'Byrne K; Stahel R; Peters S; Felip E;
Ann Oncol; 2014 Sep; 25(9):1681-1690. PubMed ID: 24718890
[TBL] [Abstract][Full Text] [Related]
7. Clinical Utility of Reflex Ordered Testing for Molecular Biomarkers in Lung Adenocarcinoma.
Anand K; Phung TL; Bernicker EH; Cagle PT; Olsen RJ; Thomas JS
Clin Lung Cancer; 2020 Sep; 21(5):437-442. PubMed ID: 32600793
[TBL] [Abstract][Full Text] [Related]
8. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer.
Lim C; Tsao MS; Le LW; Shepherd FA; Feld R; Burkes RL; Liu G; Kamel-Reid S; Hwang D; Tanguay J; da Cunha Santos G; Leighl NB
Ann Oncol; 2015 Jul; 26(7):1415-21. PubMed ID: 25922063
[TBL] [Abstract][Full Text] [Related]
9. Multiple Biomarker Testing Tissue Consumption and Completion Rates With Single-gene Tests and Investigational Use of Oncomine Dx Target Test for Advanced Non-Small-cell Lung Cancer: A Single-center Analysis.
Yu TM; Morrison C; Gold EJ; Tradonsky A; Layton AJ
Clin Lung Cancer; 2019 Jan; 20(1):20-29.e8. PubMed ID: 30243889
[TBL] [Abstract][Full Text] [Related]
10. Strategic management of transthoracic needle aspirates for histological subtyping and EGFR testing in patients with peripheral lung cancer: An institutional experience.
Son C; Kang EJ; Roh MS
Diagn Cytopathol; 2015 Jul; 43(7):532-8. PubMed ID: 25427228
[TBL] [Abstract][Full Text] [Related]
11. Lung cancer cytology and small biopsy specimens: diagnosis, predictive biomarker testing, acquisition, triage, and management.
Sung S; Heymann JJ; Crapanzano JP; Moreira AL; Shu C; Bulman WA; Saqi A
J Am Soc Cytopathol; 2020; 9(5):332-345. PubMed ID: 32591241
[TBL] [Abstract][Full Text] [Related]
12. Non-Small Cell Lung Cancer, Version 4.2024, NCCN Clinical Practice Guidelines in Oncology.
Riely GJ; Wood DE; Ettinger DS; Aisner DL; Akerley W; Bauman JR; Bharat A; Bruno DS; Chang JY; Chirieac LR; DeCamp M; Desai AP; Dilling TJ; Dowell J; Durm GA; Gettinger S; Grotz TE; Gubens MA; Juloori A; Lackner RP; Lanuti M; Lin J; Loo BW; Lovly CM; Maldonado F; Massarelli E; Morgensztern D; Mullikin TC; Ng T; Owen D; Owen DH; Patel SP; Patil T; Polanco PM; Riess J; Shapiro TA; Singh AP; Stevenson J; Tam A; Tanvetyanon T; Yanagawa J; Yang SC; Yau E; Gregory KM; Hang L
J Natl Compr Canc Netw; 2024 May; 22(4):249-274. PubMed ID: 38754467
[TBL] [Abstract][Full Text] [Related]
13. Molecular Testing Turnaround Time in Non-Small-Cell Lung Cancer: Monitoring a Moving Target.
VanderLaan PA; Chen Y; DiStasio M; Rangachari D; Costa DB; Heher YK
Clin Lung Cancer; 2018 Sep; 19(5):e589-e590. PubMed ID: 29798809
[No Abstract] [Full Text] [Related]
14. EBUS-TBNA provides highest RNA yield for multiple biomarker testing from routinely obtained small biopsies in non-small cell lung cancer patients - a comparative study of three different minimal invasive sampling methods.
Schmid-Bindert G; Wang Y; Jiang H; Sun H; Henzler T; Wang H; Pilz LR; Ren S; Zhou C
PLoS One; 2013; 8(10):e77948. PubMed ID: 24205040
[TBL] [Abstract][Full Text] [Related]
15. Untangling the evolutionary roots of lung cancer.
Devarakonda S; Govindan R
Nat Commun; 2019 Jul; 10(1):2979. PubMed ID: 31278259
[TBL] [Abstract][Full Text] [Related]
16. Current and future trends in non-small cell lung cancer biomarker testing: The American experience.
VanderLaan PA; Roy-Chowdhuri S
Cancer Cytopathol; 2020 Sep; 128(9):629-636. PubMed ID: 32885913
[TBL] [Abstract][Full Text] [Related]
17. What, When, and How of Biomarker Testing in Non-Small Cell Lung Cancer.
Riely GL
J Natl Compr Canc Netw; 2017 May; 15(5S):686-688. PubMed ID: 28515244
[TBL] [Abstract][Full Text] [Related]
18. Tumor acquisition for biomarker research in lung cancer.
Stevenson M; Christensen J; Shoemaker D; Foster T; Barry WT; Tong BC; Wahidi M; Shofer S; Datto M; Ginsburg G; Crawford J; D'Amico T; Ready N
Cancer Invest; 2014 Jul; 32(6):291-8. PubMed ID: 24810245
[TBL] [Abstract][Full Text] [Related]
19. Yield and Clinical Utility of Next-Generation Sequencing in Selected Patients With Lung Adenocarcinoma.
DiBardino DM; Saqi A; Elvin JA; Greenbowe J; Suh JH; Miller VA; Ali SM; Stoopler M; Bulman WA
Clin Lung Cancer; 2016 Nov; 17(6):517-522.e3. PubMed ID: 27378171
[TBL] [Abstract][Full Text] [Related]
20. Adequacy of small biopsy and cytology specimens for comprehensive genomic profiling of patients with non-small-cell lung cancer to determine eligibility for immune checkpoint inhibitor and targeted therapy.
Faber E; Grosu H; Sabir S; San Lucas FA; Barkoh BA; Bassett RL; Luthra R; Stewart J; Roy-Chowdhuri S
J Clin Pathol; 2022 Sep; 75(9):612-619. PubMed ID: 33952592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
